HeartBeam (BEAT) Stock News Today: FDA Clearance Ignites Rally, Analysts Lift Targets, and What Investors Are Watching Next (Dec. 17, 2025)
December 17, 2025 — HeartBeam, Inc. has moved from “interesting microcap medtech story” to “market’s attention magnet” in a hurry. The spark: FDA 510 clearance for HeartBeam’s 12-lead ECG synthesis software for at-home arrhythmia assessment, granted after the company successfully appealed a prior “Not Substantially Equivalent” outcome. HeartBeam, Inc.
